Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon‐like peptide‐1 receptor agonists

Aim To evaluate the generalizability of cardiovascular outcome trials (CVOTs) on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), we assessed what proportion of real‐world patients with type 2 diabetes (T2D) constitute true CVOT‐like populations. Materials and Methods We applied inclusion/exclusion (I/E) criteria of each GLP‐1RA CVOT to a cross‐sectional database of 281 380 T2D patients from Italian diabetes outpatient clinics. We...